Inverna Therapeutics will participate in BIO-Europe 2025

Odense, Denmark – October 05 , 2025 – Inverna Therapeutics is pleased to announce its participation in BIO-Europe 2025, Europe’s leading biotech partnering event, held November 3–5, 2025, in Vienna, Austria.
This opportunity will enable Inverna to highlight its cutting-edge RNA therapeutic program featuring gene expression modulation through precise pseudo-exon activation.
“We look forward to engaging with key stakeholders and advancing collaborations,” said Poul Sørensen, CEO. Inverna welcomes meeting requests through the BIO-Europe partnering platform.

About Inverna Therapeutics
Inverna Therapeutics is a Danish biotech company, founded in 2024 and based in Odense. With its proprietary drug discovery platform, Inverna is dedicated to developing transformative RNA therapeutics based on RNA splicing modulation. The company aims to rapidly design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. With a strong scientific foundation and an experienced, talented team, Inverna is committed to advancing novel RNA therapeutics and bringing hope to patients.